

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
11 April 2024 (11.04.2024)



(10) International Publication Number
WO 2024/075003 A1

(51) International Patent Classification:

A61K 38/38 (2006.01) A61K 31/201 (2006.01)
A61P 35/00 (2006.01)

DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2023/059909

(22) International Filing Date:

03 October 2023 (03.10.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

2214514.8 03 October 2022 (03.10.2022) GB
2219335.3 21 December 2022 (21.12.2022) GB

(71) Applicant: LINNANE PHARMA AB [SE/SE]; Slottsgatan 32, 21133 Malmö (SE).

(72) Inventors: SVANBORG, Catharina; c/o Department of Microbiology, Immunology and Glycobiology (MIG), Institute of Laboratory Medicine, Lund University, S-223 62 Lund Solvegatan 23 (SE). HIEN, Tran Thi; c/o Department of Microbiology, Immunology and Glycobiology (MG), Institute of Laboratory Medicine, Lund University, S-223 62 Lund, Solvegatan 23 (SE).

(74) Agent: GREAVES BREWSTER LLP; Copa House, Station Road, Cheddar Somerset BS27 3AH (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE



WO 2024/075003 A1

(54) Title: A COMPLEX COMPRISING A ALPHA-LACTALBUMIN AND A FATTY ACID OR LIPID FOR USE IN THE TREATMENT OR PREVENTION OF CANCER

(57) Abstract: The invention provides a complex for use in various therapeutic applications, and methods of treatment using the complex, or pharmaceutical compositions comprising the complex. The complex is particularly useful for treating malignant transformations, particularly cancer, especially where such transformations are found at a site distant from the site of administration of the complex, as well as for the treatment of metabolic-related conditions. The complex comprises a polypeptide having a sequence of a naturally occurring alpha- lactalbumin, or a functional variant thereof; or a peptide of up to 50 amino acids comprising an alpha-helical domain of said polypeptide; and a fatty acid or lipid or salt thereof